Colleen Watt

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer”.

Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer

New England Journal of Medicine(2023)10.1056/nejmoa2212083

N/A

7.7DataRank · unranked

1042 citations

Xiaofei Wang, David Kozono, Colleen Watt, Rodney Landrenau, Dennis A. Wigle +16 more

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

New England Journal of Medicine(2024)10.1056/nejmoa2401726

N/A

3.9DataRank · unranked

151 citations

Karla V. Ballman, Guru Sonpavde, Stephanie Berg, William Y. Kim, Rahul Atul Parikh +35 more

Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer

Clinical Lung Cancer(2022)10.1016/j.cllc.2022.04.004

N/A

0.662DataRank · unranked

19 citations

Xiaofei Wang, Christine M. Bestvina, Terence M. Williams, Greg Masters, Anurag Kumar Singh +10 more

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.tps760

N/A

0DataRank · unranked

13 citations

Karla V. Ballman, Atish D. Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen +7 more

Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps5107

N/A

0DataRank · unranked

4 citations

Glenn Heller, Charles J. Ryan, David James VanderWeele, Lionel D. Lewis, Alan Tan +10 more

Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps8602

N/A

0DataRank · unranked

3 citations

Xiaofei F. Wang, Dennis A. Wigle, Colleen Watt, Gregory A. Masters, Kathryn L. Kelley +3 more

Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps194

N/A

0DataRank · unranked

5 citations

Glenn Heller, Charles J. Ryan, David James VanderWeele, Lionel D. Lewis, Alan Tan +10 more

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps5100

N/A

0DataRank · unranked

9 citations

Karla V. Ballman, Atish D. Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen +8 more

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.tps366

N/A

0DataRank · unranked

26 citations

Karla V. Ballman, Atish D. Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen +8 more